Takeda Pharmaceutical

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:20 p.m. ET on Monday, January 11, 2021 / 7:20 a.m. JT on Tuesday, January 12, 2021. Investors and the general public are invited to listen to the live webcast with Christophe Weber, president and chief executive officer, here. A replay of the webcast will also be archived at the same location. A

Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select prescription products to Cheplapharm for a total value of $562 million USD1. The portfolio includes 16 prescription pharmaceutical products sold predominantly in Europe which is part of Takeda's Europe and Canada Business Unit. This divestment agreement was first announced in September 2020. The divested port

Takeda Completes Sale of Select Non-Core Assets to Cheplapharm

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co., Ltd. (China) (“Hasten”), a company funded by Feidong County of Hefei City, China and established by Ray Capital Management Limited (“Ray Capital”)1 Takeda will receive $322 million USD, subject to customary legal and regulatory c

Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) for adult patients with chronic-phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors. The updated label includes an optimized, response-based ICLUSIG dosing regimen in CP-CML with a d

U.S. FDA Approves Supplemental New Drug Application for Takeda's ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) and granted Priority Review for the investigational therapy budesonide oral suspension, TAK-721, which has been designed specifically for eosinophilic esophagitis (EoE).1 If approved, TAK-721 will be the first FDA-approved treatment for the chronic infl

U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda's TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis

Japan's Takeda Pharmaceutical Co said on Wednesday its drug pipeline is poised to drive annual sales up by more than 50%, to 5 trillion yen ($48.01 billion) in the next decade.

Japan's Takeda says drug pipeline to lift sales to $48 billion in next decade

OSAKA, Japan--(BUSINESS WIRE)--As part of its Wave 1 Pipeline Market Opportunity Call, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) provided an update on its pipeline portfolio, which has the potential to contribute significantly to revenue growth for the company over the next decade. The company also shared its PTS adjusted2 view for FY2019-FY2030 revenue CAGR (low single-digit), as well as its goal for FY2019-FY2030 revenue CAGR (mid-single-digit), amounting to JPY5 tr

Takeda's Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade

SHANGHAI & OSAKA, Japan--(BUSINESS WIRE)--Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema

Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda today presented five hematology poster presentations and four abstracts at the 62nd American Society of Hematology (ASH) Annual Meeting.

Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding Disorders

CAMBRIDGE, Mass. and OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. availability of myPKFiT® for ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated], a web-based software and mobile application that is the first and only pharmacokinetic (PK)-dosing software approved by the U.S. Food and Drug Administration (FDA) for hemophilia A patients 12 and older and weighing at least 29 kg treated with ADYNOVATE.1 The myP

Takeda Further Enables Hemophilia A Personalized Care With Launch of myPKFiT® Software for ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated]

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Celltrion Inc. (“Celltrion”) for a total value of $278 million USD inclusive of milestone payments. The portfolio includes 18 pharmaceutical products and over-the-counter (OTC) products sold in Asia Pacific, which is part of Takeda's Growth & Emerging Markets Business Unit. This divestment agr

Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific

INCHEON, South Korea--(BUSINESS WIRE)-- #Acquisition--Celltrion completed an acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited.

Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited

Amgen

THOUSAND OAKS, Calif., Nov. 30, 2020 /PRNewswire/ -- Three members of the COVID R&D Alliance - Amgen Inc. (NASDAQ: AMGN), Takeda Pharmaceutical Co. Ltd. (NYSE: TAK), and UCB (Euronext BR: UCB) - today announced the first patient enrolled in the COMMUNITY Trial (COVID-19 Multiple Agents...

World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19

PARIS--(BUSINESS WIRE)--Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has achieved the first milestone in its strategic research alliance with Takeda Pharmaceutical Company Limited (“Takeda”). In the course of the strategic research alliance that was announced in June 2020, Egle will validate novel tumor-infil

Egle Therapeutics Identifies First Novel Regulatory T-cell Targets in Research Alliance with Takeda

AstraZeneca

BioNTech SE

Moderna

Novavax

Pfizer

The numbers are close, but two players stand out at the moment.

Which Coronavirus Vaccine Maker Is Poised to Be the Top Supplier?

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced it will present nine company-sponsored abstracts at the 62nd American Society of Hematology (ASH) Annual Meeting, being held virtually for the first time December 5-8, 2020. These data span Takeda's extensive hematology portfolio and R&D pipeline, featuring results across various bleeding disorders, including hemophilia A, von Willebrand disease and sickle cell diseas

Takeda to Highlight Research Commitment in Bleeding Disorders and Personalized Care at American Society of Hematology (ASH) Virtual Annual Meeting

Japan's Takeda Pharmaceutical Co is looking at making vaccines a core business after completing asset sales to lower debt following its takeover of Shire Plc, Chief Executive Christophe Weber said.

Japan's Takeda eyes new focus on vaccines after OTC asset sales: CEO

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present 22 company-sponsored abstracts at the 62nd American Society of Hematology (ASH) Annual Meeting, being held virtually December 5-8, 2020. The company's scientific research at ASH will identify unique approaches in advancing the treatment of hematologic cancers, illustrative of its commitment to developing and providing transformative solution

Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting

Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q2 2021 Results - Earnings Call Transcript

SAN DIEGO, Oct. 29, 2020 /PRNewswire/ -- Seqster PDM Inc. ("Seqster") the award winning healthcare technology company and Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda") announced today an extended agreement to improve patient outcomes through better access and...

Seqster Partners with Takeda to Help Digitally Transform Patient Experiences

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first half of fiscal year 2020 (period ended September 30, 2020). TAKEDA PRESIDENT & CHIEF EXECUTIVE OFFICER CHRISTOPHE WEBER commented: “Takeda's performance in the first half of FY2020 demonstrates the resilience of our business model, the depth of our portfolio and the commitment of our employees, who continue to serve patients and communities glob

Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts for Free Cash Flow, Reported OP & Reported EPS

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), announced today that it will import and distribute 50 million doses of Moderna's COVID-19 vaccine candidate, mRNA-1273, starting in the first half of 2021, pending licensure in Japan. This effort is part of a three-way agreement among Takeda, Moderna and the Government of Japan's Ministry of Health Labour and Welfare (MHLW). Moderna has previously announced that the 30,000 participant Phase 3 clinical tria

Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna partners with Takeda and the government of Japan to supply 50 million doses of mRNA vaccine against COVID-19 (mRNA-1273) to Japan.

Moderna Partners with Takeda and the Government of Japan to Supply 50 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) to Japan

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented four abstracts at the Thrombosis and Hemostasis Summit of North America (THSNA), highlighting Takeda's commitment to advancing personalized care in people living with bleeding disorders. These studies may help provide further data to healthcare providers regarding treatment personalization in patients with hemophilia and von Willebrand's disease (VWD). “When l

Takeda Presents Rare Bleeding Disorders Research at Thrombosis & Hemostasis Summit of North America (THSNA) 2020

Accenture Plc

OSAKA, Japan & NEW YORK & SEATTLE--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”), Accenture (NYSE: ACN) and Amazon Web Services, Inc. (AWS) have entered into a five-year strategic agreement to accelerate Takeda’s digital transformation. Not only will patients benefit from Takeda’s ability to respond with greater speed, agility, and insights across the value chain, but customers, employees, and partners will also benefit. This long-term collaboration wil

News for Takeda Pharmaceutical Stock (TAK)